One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient Registry.

Abstract

We studied the progression of myasthenia gravis (MG) disease burden and medication adjustment among MG Patient Registry participants. Participants diagnosed with MG (age ≥18 years), registered between July 1, 2013 and July 31, 2018 and completing both 6- and 12-month follow-up surveys, were included in this investigation. Participants were grouped into high-burden (Myasthenia Gravis Activity of Daily Living scale [MG-ADL] score ≥6) and low-burden (MG-ADL <6) groups based on MG-ADL scores at enrollment. Demographics and disease history were compared between groups. MG-ADL score change and medication changes (escalation, no change, de-escalation) between enrollment and 12-month follow-up were compared between groups. Minimal symptom expression (MSE, MG-ADL <2) at 12 months was compared between groups. Logistic regression analysis was performed to study factors associated with MSE at 12 months. In total, 520 participants (56% female) were included in high-burden (n=248) and low-burden (n=272) groups. Those in the high-burden group were more likely to be younger, female, and have shorter disease duration. At 12 months, MSE was achieved in 6% of the high-burden group and newly achieved (42 of 201, 21%) or maintained (52 of 71, 73%) in the low-burden group. In the multivariable analysis, being in the high-burden group and use of pyridostigmine were associated with less likelihood of MSE, whereas MG-ADL score improvement (>2 or >20%) at 6months significantly increased the likelihood of achieving MSE at 12 months (P= .0004). In both groups, but more so in the high-burden group, patients infrequently achieved MSE after 1year of MG treatment. Baseline low disease burden, improvement at 6months and no pyridostigmine use were associated with a higher likelihood of MSE at 12 months.